Literature DB >> 10689165

A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan.

T Yagi1, H Kurokawa, N Shibata, K Shibayama, Y Arakawa.   

Abstract

We conducted a survey of extended-spectrum beta-lactamases (ESBLs) among 16805 Escherichia coli and 9794 Klebsiella pneumoniae clinical isolates recovered from 196 separate medical institutions during the period January 1997 to January 1998. Using the criteria for minimal inhibitory concentrations (MICs) of oxyimino-cephalosporins of >/=8 microg ml(-1) and confirmation by double-disk test, we detected 15 E. coli and 34 K. pneumoniae isolates producing ESBLs. Genotypes of ESBLs determined by PCR with type-specific primers included one TEM-derived and 24 SHV-derived ESBLs, in addition to 24 Toho-1-type ESBLs, one of the major types of ESBLs reported in Japan. Nucleotide sequence analysis of SHV-specific PCR products revealed that SHV-12 was the dominant type of SHV-derived ESBL. In addition, we also identified TEM-26 and SHV-2. This is the first report characterizing TEM- and SHV-derived ESBLs in Japan.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10689165     DOI: 10.1111/j.1574-6968.2000.tb08989.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  54 in total

1.  A new SHV-derived extended-spectrum beta-lactamase (SHV-24) that hydrolyzes ceftazidime through a single-amino-acid substitution (D179G) in the -loop.

Authors:  H Kurokawa; T Yagi; N Shibata; K Shibayama; K Kamachi; Y Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China.

Authors:  Aroonwadee Chanawong; Fatima Hannachi M'Zali; John Heritage; Jian-Hui Xiong; Peter Michael Hawkey
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 4.  Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes.

Authors:  R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

5.  Epidemiology of extended-spectrum beta-lactamases in Sofia, Bulgaria.

Authors:  G A Jacoby; R Vacheva-Dobrevsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-29       Impact factor: 3.267

6.  A new TEM-derived extended-spectrum beta-lactamase (TEM-91) with an R164C substitution at the omega-loop confers ceftazidime resistance.

Authors:  Hiroshi Kurokawa; Naohiro Shibata; Yohei Doi; Keigo Shibayama; Kazunari Kamachi; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

7.  Molecular analysis of the simultaneous production of two SHV-type extended-spectrum beta-lactamases in a clinical isolate of Enterobacter cloacae by using single-nucleotide polymorphism genotyping.

Authors:  Dóra Szabó; Melissa A Melan; Andrea M Hujer; Robert A Bonomo; Kristine M Hujer; Christopher R Bethel; Katalin Kristóf; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

8.  PCR classification of CTX-M-type beta-lactamase genes identified in clinically isolated gram-negative bacilli in Japan.

Authors:  Naohiro Shibata; Hiroshi Kurokawa; Yohei Doi; Tetsuya Yagi; Kunikazu Yamane; Jun-ichi Wachino; Satowa Suzuki; Kouji Kimura; Satoshi Ishikawa; Haru Kato; Yoshiyuki Ozawa; Keigo Shibayama; Kumiko Kai; Toshifumi Konda; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

9.  Extended-spectrum beta-lactamase-producing Shiga toxin gene (Stx1)-positive Escherichia coli O26:H11: a new concern.

Authors:  Yoshikazu Ishii; Soichiro Kimura; Jimena Alba; Katsuaki Shiroto; Masanobu Otsuka; Naotaka Hashizume; Kazumichi Tamura; Keizo Yamaguchi
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

10.  In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.

Authors:  Akihiro Morinaka; Yuko Tsutsumi; Keiko Yamada; Yoshihiro Takayama; Shiro Sakakibara; Toshihiko Takata; Takao Abe; Takeshi Furuuchi; Seiichi Inamura; Yoshiaki Sakamaki; Nakako Tsujii; Takashi Ida
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.